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Exploring experimental cerebral 
malaria pathogenesis through the 
characterisation of host-derived 
plasma microparticle protein 
content
Natalia Tiberti1,2, Sharissa L. Latham2, Stephen Bush3, Amy Cohen2, Robert O. Opoka4, 
Chandy C. John5,6, Annette Juillard2, Georges E. Grau2,7 & Valéry Combes1,2,7
Cerebral malaria (CM) is a severe complication of Plasmodium falciparum infection responsible 
for thousands of deaths in children in sub-Saharan Africa. CM pathogenesis remains incompletely 
understood but a number of effectors have been proposed, including plasma microparticles (MP). MP 
numbers are increased in CM patients’ circulation and, in the mouse model, they can be localised within 
inflamed vessels, suggesting their involvement in vascular damage. In the present work we define, for 
the first time, the protein cargo of MP during experimental cerebral malaria (ECM) with the overarching 
hypothesis that this characterisation could help understand CM pathogenesis. Using qualitative and 
quantitative high-throughput proteomics we compared MP proteins from non-infected and P. berghei 
ANKA-infected mice. More than 360 proteins were identified, 60 of which were differentially abundant, 
as determined by quantitative comparison using TMTTM isobaric labelling. Network analyses showed 
that ECM MP carry proteins implicated in molecular mechanisms relevant to CM pathogenesis, including 
endothelial activation. Among these proteins, the strict association of carbonic anhydrase I and S100A8 
with ECM was verified by western blot on MP from DBA/1 and C57BL/6 mice. These results demonstrate 
that MP protein cargo represents a novel ECM pathogenic trait to consider in the understanding of CM 
pathogenesis.
Malaria infection caused by Plasmodium protozoan parasites still represents a major worldwide health problem 
affecting more than 200 million people and being responsible for the death of 600,000 of them, according to 
the latest WHO estimations1. Cerebral malaria (CM) is the most fatal malaria complication and affects mainly 
children under the age of 5 in sub-Saharan Africa2. CM prompt diagnosis remains difficult2 and despite availa-
ble treatment, 15–20% of patients die, while 10–15% of cured patients will suffer from long-term neurological 
deficits3.
The pathological mechanisms of this complex neurological syndrome are still to be fully deciphered. The best 
described processes of CM pathogenesis include the sequestration of parasitized red blood cells (pRBC) in the 
brain microvasculature and an excessive activation of the immune response with production of pro-inflammatory 
cytokines4. An additional important feature is the increased number of microparticles (MP) in patients’ circula-
tion. MP are submicron extracellular vesicles (100–1000 nm in size) released through a mechanism of outward 
blebbing of the plasma membrane by potentially all host cell types under physiological conditions or follow-
ing stress and apoptosis5. Due to their process of formation, MP expose on their surface negatively charged 
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phosphatidylserine residues and cellular markers specific to their cell of origin6. Importantly, they contain pro-
teins, nucleic acids and lipids derived from the cytoplasm of the parent cell that they can convey to target cells, 
thus playing an important role in the intercellular communication and exchange of biological information7 as 
already shown in cancers, neurological disorders and cardiovascular diseases8–10. Interestingly, the proteomics 
characterisation of the cargo of plasma MP released under specific pathological conditions has already been 
found useful to identify new disease biomarkers and to propose new pathophysiological features11,12.
In CM patients, an increased number of MP originating from platelets, endothelial cells, monocytes and red 
blood cells has been shown in different clinical cohorts, where a significant correlation with the disease severity 
was proven13–15. Studies in the murine model of CM (experimental cerebral malaria – ECM), consisting of sus-
ceptible mouse strains (DBA/1, CBA and C57BL/6) infected with the Plasmodium berghei ANKA (PbA) para-
site16, significantly contributed to further demonstrating that MP are not merely inert cellular products but active 
players in CM progression17,18. Indeed, similarly to human CM, increased numbers of cell-specific MP have been 
detected in ECM18 and mice showing a reduced release of MP (ABCA1−/− or pantethine-treated) are protected 
from the cerebral syndrome17,19. Additionally, adoptively transferred ECM plasma MP localised in inflamed ves-
sels, elicited breakdown of the blood brain barrier and brain pathology similar to ECM18.
Although an important role of circulating MP in CM pathogenesis is now generally accepted20,21, the mech-
anisms through which these vesicles carry out their biological functions still need to be deciphered and their 
protein cargo is yet to be described. In this context, we hypothesized that the protein content of circulating 
host-derived MP produced during CM might be of central importance in the pathogenesis of this syndrome. 
To closely follow the development of the neurological syndrome, we took advantage of the well-established CM 
mouse model and we investigated the protein content of MP produced during ECM using high-throughput qual-
itative and quantitative proteomics and network analyses. Two selected ECM-MP proteins, carbonic anhydrase 
1 (CA-I) and S100A8, were further verified on a larger number of samples and their abundance was proven to be 
increased within plasma MP specifically released during the infection.
Results
Experimental design. To obtain quantitative information on the protein cargo of MP released during dif-
ferent infection conditions we used the Tandem Mass TagTM (TMT) isobaric labelling technology (ThermoFisher 
Scientific).
To set up an efficient quantitative protocol to analyse plasma MP proteins obtained from individual mice, the 
TMTzero (TMT0) labelling approach was first applied. MP from one non-infected (NI) and one PbA-infected 
mouse (experimental cerebral malaria – ECM) were used. The lists of identified proteins were considered as 
“qualitative datasets”.
The protocol established with the TMT0 was then translated to the TMTsixplex (TMT6) format. To increase 
the number of tested samples, two parallel experiments were performed comparing plasma MP proteins from 
non-infected mice (NI, n = 4), PbA-infected mice at day 3 post-infection (d3 pi, n = 4) and PbA-infected mice at 
d8 post-infection when all the signs of cerebral malaria are detected (ECM, n = 4).
Qualitative and quantitative proteomics results were then compared and evaluated in the context of CM 
pathogenesis through gene ontology and network analyses, and further verified by western blot (WB) for two 
selected proteins, carbonic anhydrase I (CA-I) and S100A8 on two different mouse strains.
A graphical representation of the experimental design used in the present study is depicted in Fig. 1.
MP visualisation by scanning electron microscopy (SEM) and counting by flow cytometry. To 
demonstrate the efficiency of our purification method, plasma MP from a NI mouse were imaged by SEM (Fig. 2). 
Figure 2A and C clearly show that the predominant population of purified vesicles has a size range compatible to 
that of MP (0.1–1 μ m); only a minimal contamination of larger elements, which might correspond to cell debris 
or platelets, was visualised.
When counted by flow cytometry in PFP samples, the number of Annexin V+ MP/μ L in ECM PFP was 2.5 
and 2.1 times higher than in NI and d3 pi PFP, respectively (Supplementary Figure S1).
Proteomics analyses. TMT0 qualitative experiment. In the TMT0 experiment we identified 184 NI MP 
proteins and 164 ECM MP proteins (2 unique peptides, FDR ≤ 1%, Fig. 3A).
The complete lists of identified proteins together with the identification details are reported in Supplementary 
MS Information-Identification. The percentage of TMT tagging – calculated as the proportion of peptides having 
a TMT0 at the N-terminus within the total identified peptides – was ≥ 97% in both samples, demonstrating the 
feasibility of the approach.
The comparison of the identified proteins between the two samples showed that 44% of the identifications 
were shared, 32% were only identified in the NI sample and 24% only in the ECM sample.
TMT6 quantitative experiments. In the two TMT6 quantitative experiments (TMT6-1 and TMT6-2), 314 proteins 
were overall identified with at least 2 unique peptides and FDR ≤ 1%. The good technical efficiency of the TMT6 
experiments was evaluated through the percentage of labelled peptides (≥ 94%) and the distribution, across the 
6 tags, of the mean relative intensity obtained for the spiked bovine beta-lactoglobulin (coefficient of variation – 
CV < 20%).
Considering the two TMT0 and the two TMT6 experiments together, we globally identified 368 murine plasma 
MP proteins (2 unique peptides, FDR ≤ 1%) (Fig. 3B).
Quantitative information was obtained for 221 and 240 proteins in the TMT6-1 and TMT6-2 experiments, 
respectively and, of these, 67% were commonly quantified in the two experiments. Among all quantified proteins 
(TMT6-1 + TMT6-2), 60 were significantly different in abundance (Mann-Whitney U test, p ≤ 0.001) according to 
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IsoQuant statistics and the calculated ratio threshold of 2.1 for increased proteins and 0.5 for decreased proteins 
(Fig. 3C,D and Supplementary MS information-Quantification). When the ECM/d3 pi ratio was considered, 38 
proteins had significantly increased and 7 significantly decreased abundance. Thirty-one proteins were increased 
in ECM compared to NI MP, 26 of which had also higher abundance in ECM compared to d3 pi, and 12 proteins 
had an ECM/NI ratio ≤ 0.5. Finally, for the comparison d3 pi/NI, 8 proteins were significantly decreased and none 
were significantly increased, indicating that this is likely too early a time point in the infection to detect differ-
ences in MP cargo. This is in agreement with previous results on the number and phenotype of circulating MP 
Figure 1. Experimental design. Graphical summary of the experimental design applied in the present 
study. PFP = platelet free plasma; MP = microparticle; SEM = scanning electron microscopy; NI = non-
infected; d3 pi = day 3 post-infection; ECM = experimental cerebral malaria (d8 post-infection). The mouse 
image was obtained at Pixabay.com.
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in ECM18. The complete list of proteins whose abundance in MP was significantly affected during the infection is 
reported in Fig. 3D.
When Plasmodium berghei proteins were searched, two proteins - intra-erythrocytic P. berghei-induced 
structures protein 1 and merozoite surface protein-1 - were detected (2 unique peptides, FDR ≤ 1%) in 
the TMT0 ECM sample, after exclusion of all peptides also matching murine proteins (Supplementary MS 
information-Identification). In all other samples, no parasite protein could be identified with sufficient 
confidence.
The mass spectrometry data have been deposited to the ProteomeXchange Consortium (http://proteome cen-
tral.proteomexchange.org)22 via the PRIDE partner repository23 with the dataset identifier PXD003772.
Gene Ontology analysis. All murine plasma MP proteins identified in our proteomics experiments 
(n = 368) were subjected to Gene Ontology (GO) analysis. For each GO category (i.e., biological process – BP, 
molecular function – MF and cellular component – CC), the top-10 most represented GO terms are reported in 
Fig. 4.
As shown, the majority of plasma MP proteins were involved in localisation processes and in response to stim-
ulus, with the immune and inflammatory responses appearing among the top 10 BP, probably as a contribution 
of proteins whose expression was induced by the infection. Considering the CC terms, the identified proteins 
were highly significantly associated with the cytoskeleton, the plasma membrane and vesicles. Finally, the MF 
GO terms showed that the proteins identified from murine plasma MP have important active roles, being highly 
significantly associated with binding and regulatory activities.
Network and upstream regulator analyses. To highlight proteins associated with the ECM pathological 
state, a list comprising all those significantly overabundant in ECM MP compared either to d3 pi or to NI (n = 42) 
and all proteins uniquely identified in the TMT0 ECM MP sample (n = 21) was created (ECM-associated proteins, 
Table 1). Similarly, a list of NI-associated proteins (n = 43) comprised 16 proteins significantly overabundant in 
NI MP, compared either to d3 pi or to ECM MP, and 27 only identified in NI MP (Supplementary Table 1).
The 63 ECM-associated proteins were analysed with IPA Ingenuity to highlight significantly represented net-
works and predicted upstream regulators. The top two molecular networks are reported in Fig. 5A and B and 
for each the most interesting significant molecular functions were selected. The network with the highest score 
involved 18 molecules of the experimental dataset and was associated (p < 0.0001) with molecular functions 
affecting the quantity of blood cells and of reticulocytes, and RBC morphology. The second network, involving 13 
Figure 2. Murine plasma MP visualized by Scanning Electron Microscopy. Plasma MP purified from a non-
infected DBA/1 mouse have been imaged with a Zeiss Ultra FESEM. (A,C) Magnification x4000. The majority 
of the visualized vesicles have size corresponding to MP (0.1–1 μ m - yellow arrowheads), while only one bigger 
element (white arrowheads) was visualised on each image probably corresponding to small aggregates of MP 
or microplatelets. (B,D) Visualisation of plasma MP at a higher magnification, × 23920 and 52160, respectively. 
Numbers beside arrowheads indicate the measured vesicle diameter expressed in μ m.
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molecules of the dataset, was significantly associated (p < 0.0001) with the activation of myeloid cells, leukocyte 
migration and inflammation of endothelial cells.
The upstream regulator analysis predicted, with high significance, that tumour necrosis factor (TNF), amyloid 
precursor proteins, MYC, erythroid transcription factor (GATA 1) and transforming growth factor beta (TGFβ ) 
were highly likely to regulate the expression of the proteins found to be associated with ECM MP. The detailed 
results of the upstream regulator analysis are reported in Fig. 5C.
The same analysis was performed on the list of NI-associated proteins (n = 43) and the top two networks were 
significantly associated with lipid metabolism and with haemostasis (Supplementary Figure S2).
CA-I and S100A8 verification by western blot. To verify our results, two proteins – carbonic anhydrase 
1 (CA-I) and S100A8 - were selected, based on their biological functions and proteomics results, for further eval-
uation on a larger number of newly collected samples from DBA/1 mice (n = 16). CA-I (identified with 6 peptide 
spectral matches - PSM, 4 unique peptides and 17.31% sequence coverage) was quantified in both TMT6-1 and 
-2 experiments as overabundant in ECM MP compared to both NI (ECM/NI = 2.9 and 2.4, respectively) and d3 
pi MP (ECM/d3 pi = 3.7 and 2.7, respectively). S100A8 was uniquely identified in ECM MP (3 PSM, 3 unique 
peptides and 54.55% sequence coverage).
As shown in Fig. 6, CA-I abundance was confirmed to be significantly higher in ECM MP (n = 8) compared 
to NI samples (n = 8) (t-test, p < 0.0001). A 10 kDa band corresponding to S100A8 protein was detected in all 
8 ECM samples but in only 1 out of 8 NI MP, confirming proteomics results where it was only identified in 
PbA-infected MP. Unfortunately, to the best of our knowledge, a housekeeping protein for plasma MP has not 
been described yet. When the abundance of γ -actin was assessed on the same samples, a more intense signal 
was detected in NI samples indicating that actin is not an adequate loading control due to the high variability 
Figure 3. Identification and quantification results. (A) Proteins identified in the plasma MP from a non-
infected mouse (NI) and a PbA-infected mouse at the stage of experimental cerebral malaria (ECM) (TMT0 
experiment). The two samples shared 44% of the identifications. Only proteins identified with minimum 2 
peptides and FDR ≤ 1% have been considered. (B) Comparison of the proteins identified in the pooled NI – d3 
pi – ECM samples (TMT6#1 and TMT6#2 experiments) and those identified in the individual NI and ECM 
samples (TMT0 experiment). Globally, 368 murine plasma microparticle proteins have been identified.  
(C) Quantitative results obtained from the two TMT6 experiments. Proteins differentially abundant in MP  
were defined as having a p-value < 0.001 and a ratio ≥ 2.1 or ≤ 0.5. (D) Heat map showing the level of expression 
of the proteins found to be significantly differentially abundant for the three computed ratios, i.e. ECM/d3 pi, 
ECM/NI and d3 pi/NI, in the two quantitative experiments. nd = non differential proteins.
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in protein composition of plasma MP, but also showing that our experiments were not biased towards a higher 
amount of proteins loaded in ECM samples (Supplementary Figure S3).
S100A8 and CA-I were also assessed in the platelet-free plasma (PFP) and MP-free plasma (MFP) of 10 out 
of the 16 samples (Supplementary Figure S4). CA-I was expressed in both PFP and MFP but no difference was 
observed between the 2 types of samples (PFP vs. MFP, Wilcoxon matched-pairs signed rank test) nor between 
groups (NI vs. ECM, Mann-Whitney U test). Interestingly, S100A8 was detected in only 2 out of 5 ECM PFP (and 
in the corresponding MFP) and in none of the NI samples.
To exclude the possibility of an association between the obtained results and the DBA/1 genotype, CA-I and 
S100A8 were assessed by WB in MP and PFP samples from C57BL/6 mice (n = 4 NI, n = 4 PbA-infected - ECM) 
(Supplementary Figure S5). CA-I was significantly more abundant in both MP and PFP samples from ECM mice 
compared to NI, while S100A8 was only detected in ECM MP, confirming the results obtained by both proteom-
ics and WB in the DBA/1 model. S100A8 was not detected in the PFP of C57BL/6 mice, both NI and ECM.
Finally, the two proteins were also assessed in MP isolated from PFP obtained from children suffering either 
from CM or from asymptomatic malaria (AM), as well as from healthy community controls (CC) (n = 7 in each 
group) (Supplementary Figure S6). S100A8 was significantly (one-way ANOVA, p = 0.006) more abundant in 
MP from CM patients compared to both AM and CC (Dunnet’s multiple comparison post-test, p = 0.0069 and 
p = 0.0134, respectively). CA-I was not significantly different between the three groups, however its abundance in 
CM MP was almost double than in AM MP (mean CM/mean AM = 1.9).
Discussion
Host-derived plasma microparticles (MP) are well recognised as being involved in the pathogenesis of both 
human and experimental CM17,18,20,21, however the contribution of their protein cargo to the pathological mech-
anisms leading to this syndrome has not been deciphered yet. MP are known to contain proteins derived from 
the cell of origin, and this cargo doesn’t seem to be the consequence of a casual uptake from the parent cell’s cyto-
plasm, but rather the result of specific packaging mechanisms9,24 making these vesicles important players in inter-
cellular communication11. To try to achieve new insights into the pathogenesis of CM and to better understand 
the role of MP in this syndrome, we have established and validated a qualitative and quantitative characterisation 
of the protein content of plasma MP released during ECM. To our knowledge, this is the first time that this strat-
egy is applied to ECM and that the protein cargo of MP obtained from individual mice is successfully investigated 
by TMT quantitative proteomics. Only few other studies have used proteomics to investigate extracellular vesicles 
in malaria models, including P. yoeli-infected mice or in vitro cultured pRBC25,26.
Figure 4. Gene Ontology analysis. Top-10 GO terms represented across all 368 identified murine plasma MP 
proteins. (A) Biological Process GO terms; (B) Molecular Function GO terms; (C) Cellular Component GO terms. 
For each category only significantly represented GO terms have been considered (adjusted p-value < 0.0001) and 
the % of proteins belonging to each term is reported. *Indicates potentially relevant GO terms in the context of MP 
and ECM.
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# AC ID Description
ECM/NI Ratio ECM/d3 pi Ratio
TMT6 #1 TMT6 #2 TMT6 #1 TMT6 #2
1 P05366 SAA1_MOUSE Serum amyloid A-1 protein 4.16 3.52 4.66 4.43
2 P05367 SAA2_MOUSE Amyloid protein A 3.81 — 4.71 —
3 P01942 HBA_MOUSE Hemoglobin subunit alpha 3.56 3.51 4.16 3.14
4 P02089 HBB2_MOUSE Hemoglobin subunit beta-2 3.27 3.56 3.70 3.19
5 P00920 CAH2_MOUSE Carbonic anhydrase 2 (CA-II) 3.39 3.31 4.20 3.20
6 P01872 IGHM_MOUSE Ig mu chain C region 3.25 — 3.56 2.50
7 Q61171 PRDX2_MOUSE Peroxiredoxin-2 (TSA) 3.10 3.25 3.29 3.21
8 P02088 HBB1_MOUSE Hemoglobin subunit beta-1 2.99 3.25 3.32 2.83
9 P08113 ENPL_MOUSE Endoplasmin (GRP-94) (ERp99) 3.02 — — —
10 P04919 B3AT_MOUSE Band 3 anion transport protein, Isoform Kidney 2.37 3.25 2.83 2.73
11 Q9QWK4 CD5L_MOUSE CD5 antigen-like 2.75 — 3.22 —
12 P06800 PTPRC_MOUSE Receptor-type tyrosine-protein phosphatase C, Isoform 3 2.32 3.27 2.85 3.33
13 P09103 PDIA1_MOUSE Protein disulfide-isomerase (PDI) (ER protein 59) 2.75 — — —
14 P01837 IGKC_MOUSE Ig kappa chain C region 2.64 — 3.41 —
15 P13634 CAH1_MOUSE Carbonic anhydrase 1 (CA-I) 2.86 2.40 3.67 2.69
16 P04918 SAA3_MOUSE Serum amyloid A-3 protein 2.52 — 2.67 —
17 P01831 THY1_MOUSE Thy-1 membrane glycoprotein — 2.51 — —
18 P11835 ITB2_MOUSE Integrin beta-2 2.17 2.70 2.46 2.70
19 Q02013 AQP1_MOUSE Aquaporin-1 (AQP-1) (DER2) 2.28 2.37 3.38 2.30
20 P27773 PDIA3_MOUSE Protein disulfide-isomerase A3 (p58) (ERp57) (ERp60) 2.28 — 2.42 —
21 P01897 HA1L_MOUSE H-2 class I histocompatibility antigen, L-D alpha chain — 2.28 — —
22 P24063 ITAL_MOUSE Integrin alpha-L (LFA-1A) (Ly-15) — 2.18 2.36 2.23
23 P05555 ITAM_MOUSE Integrin alpha-M, Isoform 2 — 2.14 — 2.28
24 Q02105 C1QC_MOUSE Complement C1q subcomponent subunit C 2.13 — 2.25 —
25 P12246 SAMP_MOUSE Serum amyloid P-component (SAP) 2.12 — — —
26 P20491 FCERG_MOUSE High affinity Ig epsilon receptor subunit gamma 2.12 — 3.15 —
27 P60766 CDC42_MOUSE Cell division control protein 42 homolog — 2.12 2.19 2.17
28 P08032 SPTA1_MOUSE Spectrin alpha chain, erythrocytic 1 — 2.10 — 2.06
29 P03987 IGHG3_MOUSE Ig gamma-3 chain C region, Isoform 2 2.09 — 2.56 —
30 Q61735 CD47_MOUSE Leukocyte surface antigen CD47 (IAP) 2.08 — 2.76 —
31 P54116 STOM_MOUSE Erythrocyte band 7 integral membrane protein 2.08 — 2.30 —
32 P17182 ENOA_MOUSE Alpha-enolase (NNE) — — — 2.51
33 P07356 ANXA2_MOUSE Annexin A2 (PAP-IV) — — 2.37 2.32
34 P62880 GBB2_MOUSE Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-2 — — 2.28 —
35 Q62469 ITA2_MOUSE Integrin alpha-2 (GPIa) — — — 2.27
36 P01630 KV2A6_MOUSE Ig kappa chain V-II region 7S34.1 — — 2.23 —
37 P26041 MOES_MOUSE Moesin — — 2.30 2.15
38 P18572 BASI_MOUSE Basigin, Isoform 2 — — 2.19 —
39 P06151 LDHA_MOUSE L-lactate dehydrogenase A chain (LDH-A) (LDH-M) — — — 2.19
40 P01631 KV2A7_MOUSE Ig kappa chain V-II region 26-10 — — 2.13 —
41 P15702 LEUK_MOUSE Leukosialin (Ly-48) — — — 2.12
42 P01592 IGJ_MOUSE Immunoglobulin J chain — — 2.07 —
43 Q60963 PAFA_MOUSE Platelet-activating factor acetylhydrolase (PAF acetylhydrolase) Only ID
44 P68254 1433T_MOUSE 14-3-3 protein theta Only ID
45 Q61646 HPT_MOUSE Haptoglobin beta Only ID
46 P21981 TGM2_MOUSE Protein-glutamine gamma-glutamyltransferase 2 Only ID
47 P17156 HSP72_MOUSE Heat shock-related 70 kDa protein 2 Only ID
48 P84244 H33_MOUSE Histone H3.3 Only ID
49 P31725 S10A9_MOUSE Protein S100-A9 (MRP-14) (p14) Only ID
50 P0C0S6 H2AZ_MOUSE Histone H2A.Z (H2A/z) Only ID
51 P27661 H2AX_MOUSE Histone H2AX (H2a/x) Only ID
52 P01670 KV3AI_MOUSE Ig kappa chain V-III region PC 6684 Only ID
Continued
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Through our proteomics investigations we overall identified 368 plasma MP proteins, 290 of which were also 
quantified. These results are comparable with, or higher than, other proteomics studies on human circulating 
MP27,28 and murine plasma exosomes25. The list of identified proteins included some of the most abundant plasma 
proteins, such as albumin, which however were not significantly different between samples. Although a minimal 
contamination from plasma proteins can never be excluded, some of these proteins have already been reported to 
be present within MP even after 10 washes of the vesicle pellet or reported as part of the core proteome of human 
plasma MP27,29. When the immune-depletion of albumin and immunoglobulins was tested on our samples, the 
total number of identified proteins increased by 14% (data not shown); despite the increase in the number of 
identified proteins, such a sample preparation wouldn’t have been compatible with the downstream quantitative 
analysis of MP proteins derived from individual animals due to the limited amount of proteins available. For 
these reasons, we instead reduced the contamination of plasma proteins with two washes of the MP pellet, and we 
increased the number of identified peptides by using a long gradient at the LC-MS/MS level.
To comprehensively evaluate the MP protein cargo, we performed a gene ontology analysis and showed that 
these proteins reflect both MP mechanism of formation - with a significant representation of cytoskeletal and 
structural proteins - and their active biological functions, including binding, enzymatic and regulatory activities. 
This result further sustains that circulating MP released by the host in response to a certain stimulus, transport 
biologically active molecules that are likely to mediate physiological and pathological processes, as already pro-
posed24,30–32. Interestingly, a number of proteins already proposed to be associated with parasite virulence and 
intra-erythrocytic life stage, including basigin, peroxiredoxin 2 and aquaporin 933–35, or associated to the phe-
nomenon of adhesion to the brain microvasculature (integrins) have been identified within ECM MP.
A deeper analysis revealed that these ECM-associated proteins were interconnected in two distinct networks 
reflecting the pathological state of the sample from which they are derived. The first network involved molecules 
and pathways significantly associated with RBC number and morphology, indicating that RBC-MP represent 
an important proportion of circulating vesicles during ECM, as already reported18, and that their protein cargo 
reflects the known alteration of RBC occurring during the infection36. However, whether these proteins are specif-
ically packaged into MP to propagate the infection or are just the result of RBC rupture following the maturation 
of the parasite is still to be determined. These proteomics results were further verified through the validation of 
the increased abundance in ECM MP of carbonic anhydrase I (CA-I), a protein participating in this network. 
CA-I, mainly expressed in RBC and in the gastro-intestinal tract37, belongs to a group of proteins involved in the 
maintenance of the acid-base homeostasis of blood and tissues through the reversible catalysis of carbon dioxide 
and bicarbonate conversion38. In severe malaria, the acid-base balance is often affected, as also indicated by the 
well-reported alteration of the lactate blood levels39 and, more recently, by the association of ECM with brain 
hypoxia and acidosis40. Interestingly, CA-I transcript was found to be up-regulated in the plasma of children 
experiencing severe malaria compared to mild malaria episodes occurring later in the same subjects41, further 
suggesting an interesting role for this protein in CM and raising the possibility that its increased plasma levels 
are due to MP. In our proteomics analyses we identified and quantified both CA-I and CA-II as significantly 
over-expressed in ECM MP compared to both NI and d3 pi MP. The muscle-derived CA isoenzyme, CA-III, had 
been previously identified by affinity proteomics as increased in CM children and as a discriminator between CM 
and both severe malaria anaemia (SMA) and uncomplicated malaria (UM)42.
In our study, CA-I expression was significantly increased in ECM MP compared to NI MP from DBA/1 mice 
when assessed by WB, however its plasma levels were not different between the two conditions. This might sug-
gest that CA-I could be preferentially packaged in MP - probably derived from RBC - to be transported to other 
cells to counteract the cellular and tissue acidosis and hypoxia occurring during ECM. These results were con-
firmed in MP obtained from a different mouse strain (C57BL/6), showing that the increased CA-I expression in 
ECM MP is not genotype dependent. However, in contrast with what was obtained in DBA/1 mice, when assessed 
in plasma samples from C57BL/6 mice, CA-I concentration was higher in ECM compared to NI. More in-depth 
investigations are needed to better understand the contribution of the MP proteome within the plasma proteome.
# AC ID Description
ECM/NI Ratio ECM/d3 pi Ratio
TMT6 #1 TMT6 #2 TMT6 #1 TMT6 #2
53 P14426 HA13_MOUSE H-2 class I histocompatibility antigen, D-K alpha chain (H-2D(K) Only ID
54 P0CW03 LY6C2_MOUSE Lymphocyte antigen 6C2 (Ly-6C2) Only ID
55 Q8BFZ3 ACTBL_MOUSE Beta-actin-like protein 2 Only ID
56 P01749 HVM05_MOUSE Ig heavy chain V region 3 Only ID
57 P01646 KV5AD_MOUSE Ig kappa chain V-V region HP 123E6 Only ID
58 P27005 S10A8_MOUSE Protein S100-A8 (MRP-8) Only ID
59 P62806 H4_MOUSE Histone H4 Only ID
60 P11672 NGAL_MOUSE Neutrophil gelatinase-associated lipocalin (NGAL) Only ID
61 Q8CGP1 H2B1K_MOUSE Histone H2B type 1-K Only ID
62 P50446 K2C6A_MOUSE Keratin, type II cytoskeletal 6 A (CK-6A) Only ID
63 O08677 KNG1_MOUSE Kininogen-1 light chain, Isoform 3 Only ID
Table 1.  ECM-associated proteins. List of proteins significantly over-expressed in ECM either compared to 
d3 pi or to NI (TMT6 experiments #1 and #2) and proteins uniquely identified (Only ID) in the ECM sample 
(TMT0 experiment). —: non differential expression.
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The second network that was significantly represented among ECM-associated MP proteins comprised mol-
ecules implicated in myeloid cell migration, leukocyte activation and inflammatory response in endothelial cells. 
These functions are known to be important in the pathogenesis of both human and murine CM4,43,44 and, in 
recent years, particular attention has been paid to the role of the endothelium in CM pathogenesis45–49. The 
sequestration of different cell types at the brain microvasculature level - with predominant accumulation of pRBC 
in human CM and of leukocytes in ECM - is a typical trait of the syndrome44,47. This adhesion results in the acti-
vation of the endothelium and contributes to the endothelial damage associated with CM46,50. Interestingly, the 
association of markers of endothelial activation and of platelet adhesion with CM was also shown in patients’ 
plasma investigated by affinity proteomics42. The identification of these proteins further substantiates the active 
role of MP in ECM: by carrying important molecules between cells, MP could represent primary mediators in 
cell-to-cell interaction and activation occurring in CM.
Our hypothesis that MP contain proteins actively involved in CM pathogenesis, and in endothelial damage as 
pointed out by the network analysis, was further confirmed by the upstream regulation analysis, through which 
two of the most studied molecules in CM pathogenesis, TNF and TGFβ 1, were predicted to regulate the MP 
proteins experimentally detected as ECM-associated. TNF has been reported to be involved, at different levels, 
in both human and murine CM, including in the interaction between pRBC and leukocytes with the endothe-
lium, sequestration and the release of MP from endothelial cells20,21,51,52. Despite the role of TGFβ still being 
Figure 5. Network and upstream analyses of ECM-associated proteins. (A,B) Most relevant networks 
showing the connectivity between MP proteins experimentally identified as ECM-associated (n = 63). Red: 
proteins identified as significantly over-expressed in ECM; Green: proteins uniquely identified in the ECM 
sample; Orange: multimeric proteins for which one or more chains have been identified as over-expressed 
in ECM. The most important biological functions, associated with each network, in the context of ECM, 
are reported at the bottom of the network. Protein targets selected for verification, CA-I and S100A8, are 
highlighted by a red square. (C) Top-5 molecules that are highly significantly likely to regulate the proteins 
experimentally found to be ECM-associated. For each regulator the list of target proteins in the experimental 
dataset is given. p-value: Fisher’s exact test, indication of the overlap between the proteins in the dataset and the 
genes known to be affected by the regulator.
www.nature.com/scientificreports/
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controversial, it has been shown that, on the focal brain obstruction, TGFβ released by adherent and activated 
platelets contributes to the cerebral endothelium damage53.
To further verify our proteomics and prediction analysis results, we assessed the abundance of one of the pro-
teins involved in this second network - S100A8 - that was only identified in ECM-derived MP.
S100A8, also known as myeloid-related protein 8 (MRP-8), is a calcium-binding protein constitutively 
expressed mainly by neutrophils and monocytes54. In human cells and body fluids, it often exists as a heterodimer 
or tetramer with S100A9 (or MRP14)55, which we also identified as uniquely expressed in ECM MP. S100A8/A9 
expression can be induced in monocytes, endothelial cells, keratinocytes or epithelial cells by mediators such as 
LPS and TNF56,57 and it is often increased in acute and chronic inflammatory conditions56, including rheumatoid 
arthritis, cancers and neurological disorders58,59 where they seem to play cytokine-like pro-inflammatory effects55.
Our verification data confirmed that S100A8 was detected within ECM MP but almost absent in NI MP, in 
both DBA/1 and C57BL/6 mice. Additionally, its expression was almost not-detectable in plasma samples from 
both mouse strains, suggesting that MP might be a preferential source of plasma S100A8.
In malaria, elevated serum or plasma levels of S100A8/A9 have been reported in two different studies. 
Bordmann et al. showed that in P. falciparum malaria-infected children, S100A8/A9 serum concentration cor-
related with both parasite load and temperature, even though these criteria are no longer sufficient to assess the 
disease severity60. More recently, in PbA-infected BALB/cA mice, an accumulation of S100A8+ and S100A9+ 
macrophages in the spleen was shown, as was an increased plasma concentration of the two proteins61. In our 
study, no difference was observed in S100A8 concentration in the spleen between NI and ECM DBA/1 mice 
(WB, data not shown), however it should be noted that different mouse strains are known to react differently to 
PbA-infection.
Based on their described biological properties, S100A8/A9 might be interesting players in CM. Indeed, 
S100A8/A9 are released by circulating neutrophils and monocytes upon contact with the inflamed endothelium57 
in which they induce the transcription of genes encoding for pro-inflammatory chemokines and adhesion mole-
cules such as ICAM-162. Additionally, S100A8/A9 have been implicated in leukocyte extravasation by increasing 
the binding capacity of leukocytes to endothelial ICAM-162.
The mechanism of secretion of these proteins in the extracellular environment is still not completely charac-
terised. It has been proposed that their secretion could occur through a tubulin and calcium signalling dependent 
mechanism57,63, thus the identification of S100A8 in MP might support these pieces of evidence and represent a 
new mechanism contributing to S100A8/A9 plasma level.
In our study we focused on the characterisation of host proteins and the alteration of their abundance in MP 
during ECM infection; however, as reported in other works on the in vitro study of pRBC-MP26 or on the char-
acterisation of exosomes from P. yoelii-infected mice25, parasite proteins can also be found in extracellular vesi-
cles. Here, we identified only 2 parasite proteins (intra-erythrocytic P. berghei-induced structures protein 1 and 
Figure 6. Western blot results for CA-I and S100A8 detection in murine MP. (A) Detection of CA-I and 
S100A8 in MP samples (2.5 μ g/lane left blot image, 1.8 μ g/lane right blot image) from non-infected (− , NI, 
n = 8) and PbA-infected (+ , ECM, n = 8) DBA/1 mice. A positive control (C+ ) consisting of murine spleen 
extract was included in each experiment. (B) Quantification of CA-I expression in murine plasma MP, showing 
its significantly higher expression in ECM samples (t-test). In each boxplot mean is reported as + . (C) S100A8 
was detectable in only 1 out of 8 NI samples, while it was expressed in all ECM samples. The quantification of 
the detected bands is reported in the graph, where the horizontal line represents the median band volume and 
the error bars the interquartile range.
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merozoite surface protein-1) in ECM MP analysed using the qualitative approach, potentially as a result of a release 
of MP from pRBC. This number is lower than what was reported by others, however it should be considered that 
in order to avoid pooling of samples from multiple mice, our proteomics experiments were performed on a very 
small amount of protein (approximately 5 μ g per sample). Assuming that, similar to exosomes, circulating MP can 
contain parasite proteins, these would be a minimal proportion of the total protein cargo requiring enrichment 
and fractionation steps for their detection. Such an investigation should be done in the future to decipher the 
in vivo interaction between the host and the parasite and the role of MP in this. Interestingly, one of the two PbA 
proteins that we identified within MP was already reported in P. falciparum-infected red blood cell MP produced 
in vitro26.
Our results indicate that the protein content of host-derived plasma MP is severely altered during ECM, 
compared to the early infection, and that some of the proteins appear to be selectively packaged into these vesi-
cles during the infection. Nonetheless, complementary approaches, such as immune-staining of vesicles released 
under different infection conditions, should be used to confirm this specific packaging. To further evaluate the 
implication of MP-associated proteins, and in particular of CA-I and S100A8, in both human and murine CM, 
additional investigations are needed to establish their exact cellular source and role in disease pathogenesis, using 
in vitro and in vivo models. Despite the fact that the two proteins seem to be associated with ECM, as shown by 
our proteomics results on samples taken at day 3 post-infection, additional investigations should be done using 
non-CM models to prove the specificity of this association with the severe syndrome. Interestingly, when assessed 
in MP from human plasma samples from Ugandan children in a pilot study, the two proteins were increased in 
abundance in MP from children with CM compared to asymptomatic cases and this increase was statistically sig-
nificant for S100A8. Asymptomatic malaria has recently been pointed out as a debilitating infection that should 
be considered seriously and treated64. These observations suggest that the two proteins might not only be associ-
ated to the severe syndrome in mice, but also in humans.
By describing for the first time the protein cargo of murine MP in general and more specifically those released 
during ECM, and by highlighting new potential molecular players, our results indicate that the cargo of plasma 
MP is affected during the severe infection and should be considered in the understanding of CM pathogenesis. 
Additionally, the differences in protein expression between MP and the corresponding PFP indicate that the qual-
itative and quantitative proteomics investigation of extracellular vesicles has great potential as a complementary 
strategy to the more common plasma proteomics in biomarker discovery research, since MP are likely to contain 
molecules specific to the infection or its stage.
The results here presented pave the way to future investigations in multiple directions including the further 
translation to human clinical samples to try and understand the contribution of plasma MP proteome to malaria 
severity and to identify new prognostic markers able to predict the short and long term outcome in CM patients.
Experimental Procedures
Mice and infection. DBA/1 and C57BL/6 CM-susceptible mice were infected with Plasmodium berghei 
ANKA (PbA) strain and developed a neurological pathology 6–8 days after infection17,65. Mice were infected and 
handled as reported elsewhere18. Blood was collected retro-orbitally under isoflurane-induced general anaesthe-
sia either at day 3 post-infection (d3 pi) or at the stage of ECM (end-point) in 3.2% sodium citrate. Blood from NI 
mice was obtained following the same procedure. A total of n = 14 DBA/1 mice were used to perform proteomics 
experiments; while n = 16 DBA/1 and n = 8 C57BL/6 mice were used to perform verification experiments by WB. 
The detailed demographic description is reported in Supplementary Figure S1.
Ethical approval. All procedures performed in the present study have been approved by the Animal Ethics 
Committee of the University of Sydney (Projects n: K00/10-2010/3/5317 and K20/6-2011/3/5569) and adhered 
to the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes.
Paediatric clinical samples. Platelet free plasma samples was obtained from children enrolled between 
2008 and 2012 in Uganda in the context of a study whose details, inclusion and exclusion criteria are reported 
elsewhere66. Written informed consent was obtained from parents or guardians of study participants. The 
Institutional Review Boards for human studies at Makerere University School of Medicine (Study # 2008-033) 
and the University of Minnesota granted ethical approval for the study (Study # 0802M27022); all experiments 
were performed in accordance with relevant guidelines and regulations. The demographic description of the 
samples used in the present study is reported in Supplementary Figure S6.
MP preparation, counting by flow cytometry and visualisation by Scanning Electron Microscopy 
(SEM). MP were prepared as previously reported67. Briefly, whole blood was centrifuged at 1,500 g for 15 min 
at room temperature to obtain platelet poor plasma (PPP). PPP was then centrifuged twice at 18,000 g for 3 min to 
remove possible platelet contaminations and/or cell debris and platelet free plasma (PFP) was obtained. MP were 
finally pelleted at 18,000 g for 45 min at 15 °C. To remove possible plasma protein contaminations (not specifically 
bound to MP), MP pellet was washed twice with PBS/3.2% sodium citrate and centrifuged at 18,000 g for 45 min 
after each washing step.
The number of MP in the PFP samples used for proteomics was counted by flow cytometry using Annexin V 
binding on a Beckman Coulter GalliosTM flow cytometer as previously reported13.
To confirm that the isolated population was consistent with plasma MP, vesicles purified from a NI mouse 
were also imaged by scanning electron microscopy. Samples were prepared as reported by Latham et al. and 
imaged with the Zeiss Ultra FESEM68. Imaging was carried out at the Australian Centre for Microscopy & 
Microanalysis (ACMM), The University of Sydney, Australia.
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TMT0 experiment. A pilot experiment using the TMT0 approach was performed on MP proteins from one 
NI and one ECM mouse. For each sample, proteins were extracted from pelleted MP using repeated freeze/thaw 
cycles69, re-suspended in 0.1% Rapigest SF (Waters Corporation) in 0.1 M triethylammonium bicarbonate buffer 
(TEAB) pH 8.0, alkylated with 50 mM TCEP, reduced with 400 mM iodoacetamide and digested with 0.2 μ g/μ L 
trypsin overnight at 37 °C (Promega Corporation). Digested samples were then labelled with the TMT0 reagent 
(Thermo Fisher Scientific) following manufacturer’s instructions, except for the amount of tag used to label the 
samples. Due to the low amount of proteins in MP samples, one TMT vial (0.8 mg) was used to label two samples. 
After TMT labelling, samples were cleaned with C18 ultra-micro spin column (Harvard apparatus) and dried 
under vacuum prior to LC-MS/MS analyses.
TMT6 experiment. MP obtained from 400 μ L of PFP from n = 4 NI, n = 4 d3 pi and n = 4 ECM mice were 
used to perform two parallel TMT6 experiments (TMT6-1 and TMT6-2). Protein extraction, peptide sample 
preparation and labelling were performed as reported for the TMT0. Additionally, each sample was spiked with 
0.05 μ g of bovine beta-lactoglobulin before protein reduction as an internal control.
Samples analysed in the first TMT6 experiment (TMT6-1) were labelled as follows: NI with the tags 126 and 
127; d3 pi with the tags 128 and 129, and ECM with the tags 130 and 131. In the TMT6-2 experiment NI samples 
were labelled with the tags 128 and 129, d3 pi samples with the tags 130 and 131, and ECM samples with the tags 
126 and 127.
After labelling, samples were combined, cleaned with C18 ultra-micro spin column and dried under vacuum 
prior to LC-MS/MS analyses.
Tandem mass spectrometry analyses, protein identification and quantification. Tandem 
mass spectrometry analyses were performed on a QExactive Orbitrap Plus (Thermo Electron) equipped with 
an Ultimate 3000 HPLC and autosampler system (Dionex). Peptide samples were concentrated and desalted 
onto a micro C18 pre-column (300 μ m × 5 mm, Dionex) that was switched, after 4 min wash, into line with a 
fritless nano column (75 μ m × 15 cm) containing C18 media (1.9 μ m, 120 Å, Dr Maisch) manufactured accord-
ing to Gatlin et al.70. For the TMT6 samples, the analytical peptide separation was run for 260 min at a flow rate 
of 200 nL/min; while for the TMT0 samples, a gradient of 140 min was applied. The detailed description of the 
MS/MS settings is reported as Supplementary information. Mass spectrometry analyses were carried out at the 
Bioanalytical Mass Spectrometry Facility, University of New South Wales, Australia.
MS/MS data were analysed using EasyProt platform v2.371. Raw data were converted into.mgf files and peak 
lists generated with MS convert (ProteoWizard 3.0.7529, http://proteowizard.sourceforge.net/tools.shtml). 
Protein identifications were obtained by searching peptide spectral matches against the SwissProt/UniProt data-
base (version October 2014 - 546,790 entries) using the following settings: i) Mus musculus for the taxonomy; 
ii) trypsin as the digestion enzyme with only one missed-cleavage allowed; iii) carbamidomethylation of cysteines 
as fixed modification and oxidation of methionines as variable modification; iv) only peptides with at least 6 resi-
dues were considered for protein identification and v) the precursor ion tolerance was set to 10 ppm. Additionally, 
the TMT0 or the TMT6 modifications on lysines and peptide N-termini were added as fixed modifications in the 
respective experiments. Only proteins identified with at least 2 unique peptides and false discovery rate (FDR) 
≤ 1%, calculated as reported in71, were considered as true identification matches.
For the quantitative experiment, protein relative quantification was obtained using IsoQuant embedded in the 
EasyProt platform. All peptides corresponding to one unique entry in the job, having FDR ≤ 1% and an intensity 
signal in each of the 6 TMT tags were considered for quantification.
For each TMT6 experiments, protein relative quantification was obtained computing the protein ratios ECM/d3 pi, 
ECM/NI and d3 pi/NI after isotopic purity correction according to the algorithm given by the manufacturer. 
To reduce biases due to potential differences in protein amount among the 6 TMT channels, the reporter ion 
intensities were normalized71 prior to ratio calculation and the distribution of the relative intensities of all pep-
tides considered for protein quantification was checked for normality (Shapiro-Wilk normality test). The ratio 
threshold for considering a protein differentially abundant between the compared conditions was calculated72 
and the significance level was set at 0.01 (Mann-Whitney U test). The technical performance of the two TMT6 
experiments was evaluated through the rate of labelled peptides and the normalised relative intensity distribution 
of bovine beta-lactoglobulin across the 6 tags.
For all TMT0 and TMT6 experiments a second search against the UniProtKB/TrEMBL database (version 
December 2012 - 4,870,157 entries), choosing the Plasmodium berghei taxonomy (ID 5821) was done to search 
for parasite proteins.
Gene ontology, network and upstream regulator analyses. To highlight cellular mechanisms, bio-
logical processes and molecular functions associated with murine plasma MP proteins, the list of all identified 
proteins (TMT0 and TMT6) was submitted to gene ontology (GO) analysis using bioCompendium (http://bio-
compendium.embl.de/). Only GO terms significantly represented after correction for multiple comparisons were 
considered (adjusted p-value < 0.0001).
To evaluate the association of the identified MP proteins with CM pathology, two protein sub-datasets were 
created. A first dataset, called ECM-associated proteins, comprised all proteins found significantly over-abundant 
in ECM MP compared either to d3 pi or to NI MP in at least one of the two TMT6 quantitative experiments, 
and those exclusively identified in the ECM MP sample (TMT0 qualitative experiment). The second dataset, 
NI-associated proteins, included all proteins significantly increased in NI conditions in the TMT6 experiments 
and those only identified in the NI MP in the TMT0 experiment. Both datasets were analysed with Ingenuity® 
Pathway Analysis - IPA (Ingenuity® System, http://www.ingenuity.com). A network analysis was first performed 
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to evaluate the molecular connectivity and interaction between the proteins in the datasets. This analysis is based 
on the assumption that highly connected molecules will have a higher influence on the network and that highly 
interconnected networks will have greater biological significance. Since a network is seen as a set of pathways, the 
different molecular functions determined to be significantly associated with the network can be highlighted73,74.
To evaluate ECM- or NI-associated proteins in a broader molecular and biological context, an upstream reg-
ulator analysis was also performed listing all genes, RNAs and proteins predicted to regulate the molecules in the 
experimental dataset.
Western Blot. Murine samples. The expression of two selected candidates, S100A8 and carbonic anhydrase 
1 (CA-I), was assessed by WB in MP, PFP and MP-free plasma (MFP) samples.
MP protein concentration was determined after protein extraction using the Qubit protein assay (Life 
Technologies). For each MP sample, 1 to 2.5 μ g of proteins were separated on a polyacrylamide gel and transferred 
onto a nitrocellulose membrane. For PFP and MFP 2.5 μ L of sample were used.
CA-I was detected using a rabbit monoclonal anti-mouse CA-I antibody (0.63 μ g/mL, Abcam) and a goat 
anti-rabbit IgG DyLightTM 800 conjugated secondary antibody (0.15 μ g/mL). S100A8 was detected using a goat 
polyclonal anti-mouse S100A8 antibody (0.4 μ g/mL, R&D Systems) and an anti-goat IgG IRDye® 800 conju-
gated, diluted 1/1000. Monoclonal mAb-2A3 against γ -actin, a kind gift from Christine Chaponnier (University 
of Geneva), was used at a 0.2 μ g/mL and detected with an anti-mouse IgG DyLight 680 conjugated secondary 
antibody (0.15 μ g/mL). The fluorescent signal was detected on an Odyssey Infrared Imaging System (LI-COR 
Biosciences) and images analysed with ImageQuant TL software (GE Healthcare Life Sciences). Protein expres-
sion in MP samples was determined as the measured band volume normalised to the amount of loaded protein.
To establish the appropriate number of mice to be used in WB experiments, a sample size calculation was 
done based on the variability of the normalised relative intensities of all the peptides used to quantify CA-I in 
both TMT6 experiments, after data logarithmic transformation to obtain a normal distribution. Considering an 
average standard deviation of 0.3 and 0.7 for ECM and NI samples, respectively, a sample size of n = 8 per group 
was estimated to be sufficient to detect a significant difference at 0.05 level and a fold-change of 2 with a power of 
0.895 (two-sample t test for mean difference with unequal variances).
Human samples. MP were prepared from PFP as previously described13 and proteins extracted and measured 
as reported for the murine samples. For each sample, 2 to 3 μ g of proteins were separated on 15% polyacrylamide 
gels. As these samples were obtained from young children the volume of plasma was minimal (160 μ L), therefore 
due to the low amount of proteins obtained from CC MP, pools of two samples age and sex matched were ana-
lysed. S100A8 was detected using a rabbit polyclonal primary antibody (2.0 μ g/mL, Abcam) and a goat anti-rabbit 
IgG DyLightTM 800 conjugated secondary antibody (0.15 μ g/mL). CA-I was detected with the same antibody used 
for murine samples.
Statistical analyses were performed using GraphPad Prism 6 (GraphPad Software, Inc.). Parametric or 
non-parametric statistical tests were applied according to data distribution. Comparisons between two unpaired 
groups were performed with the t-test or the Mann-Whitney U test, while comparisons between three unpaired 
groups were performed with the one-way ANOVA test followed by the Dunnet’s multiple comparison test. Paired 
groups were compared using the Wilcoxon matched-pairs signed rank test. All tests were two-tailed and the 
p-value significance was set at < 0.05.
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